Karen Weintraub is a freelance writer based in Boston, Massachusetts.
Karen Weintraub
Freelance Writer
Simons Foundation/Freelance
From this contributor
Technique follows calcium trail to track changes in signaling
Researchers have genetically engineered neurons to fluoresce in response to the calcium signals emitted when they fire, according to a study published 18 October in Neuron.
Technique follows calcium trail to track changes in signaling
By
Karen Weintraub
24 October 2012 | 2 min read
Researchers uncover new drug target for fragile X
Deleting an enzyme that regulates protein synthesis reverses some of the molecular and behavioral deficits in a mouse model of fragile X syndrome, according to research published 2 October in Neuron.
Researchers uncover new drug target for fragile X
By
Karen Weintraub
4 October 2012 | 5 min read
Drug improves social deficits in fragile X syndrome
A drug called arbaclofen improves behavioral problems in people with fragile X syndrome, an inherited condition that can lead to mental retardation and autism, according to the results of a clinical trial published today in Science Translational Medicine. A second study published in the same journal showed that the drug restores normal brain function in a mouse model of the disorder.
Drug improves social deficits in fragile X syndrome
By
Karen Weintraub
19 September 2012 | 5 min read
Explore more from The Transmitter
Michael Shadlen explains how theory of mind ushers nonconscious thoughts into consciousness
All of our thoughts, mostly nonconscious, are interrogations of the world, Shadlen says. The opportunity to report our answers to ourselves or others brings a thought into conscious awareness.
Michael Shadlen explains how theory of mind ushers nonconscious thoughts into consciousness
All of our thoughts, mostly nonconscious, are interrogations of the world, Shadlen says. The opportunity to report our answers to ourselves or others brings a thought into conscious awareness.
By
Paul Middlebrooks
28 January 2026 | 1 min read
‘Peer review is our strength’: Q&A with Walter Koroshetz, former NINDS director
In his first week off the job, the former National Institute of Neurological Disorders and Stroke director urges U.S. scientists to remain optimistic about the future of neuroscience research, even if the executive branch “may not value what we do.”
‘Peer review is our strength’: Q&A with Walter Koroshetz, former NINDS director
In his first week off the job, the former National Institute of Neurological Disorders and Stroke director urges U.S. scientists to remain optimistic about the future of neuroscience research, even if the executive branch “may not value what we do.”
By
Angie Voyles Askham
27 January 2026 | 7 min read
Viral remnant in chimpanzees silences brain gene humans still use
The retroviral insert appears to inadvertently switch off a gene involved in brain development.
Viral remnant in chimpanzees silences brain gene humans still use
The retroviral insert appears to inadvertently switch off a gene involved in brain development.
By
Siddhant Pusdekar
27 January 2026 | 5 min read